An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases

Author(s): Nader Pazyar, Amir Feily, Reza Yaghoobi.

Journal Name: Current Clinical Pharmacology

Volume 7 , Issue 4 , 2012

Submit Manuscript
Submit Proposal

Abstract:

Interleukin (IL)-1 is a pivotal proinflammatory cytokine consisting of two molecular species, IL-1 and IL-1β. Anakinra (Kineret), a recombinant human IL-1 receptor antagonist, is regarded as a biological agent which blocks the inflammatory effects of IL-1. The aim of this review was to search the literatures and summarizes in vivo, in vitro and human studies on anakinra uses in dermatological disorders. The results show that anakinra is currently used clinically for the treatment of a variety of skin conditions such as psoriasis, atopic dermatitis, photoagaing, melanoma, Schnitzler syndrome, pyoderma gangraenosum, PAPA syndrome, hidradenitis suppurativa, lamellar ichthyosis, Sweet's syndrome, panniculitis, Muckle-Wells syndrome, familial Mediterranean fever, SAPHO syndrome and other disorders. Notably, anakinra is expensive to produce and administer. Injection is the route of therapy and allergic reaction is most possible.

Keywords: Anakinra, dermatology, interleukin-1 receptor antagonist, review, PSORIASIS, PAPA SYNDROME, ATOPIC DERMATITIS, PYODERMA GANGRAENOSUM, HIDRADENITIS SUPPURATIVA, PHOTOAGING, LAMELLAR ICHTHYOSIS, MELANOMA, SWEET'S SYNDROME.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 7
ISSUE: 4
Year: 2012
Page: [271 - 275]
Pages: 5
DOI: 10.2174/157488412803305821
Price: $58

Article Metrics

PDF: 41